Teva Pharma stock price target raised to $26 by UBS on Austedo outlook
PositiveFinancial Markets

Teva Pharmaceuticals has received a boost as UBS raised its stock price target to $26, driven by a positive outlook on its Austedo medication. This adjustment reflects confidence in Teva's growth potential and the effectiveness of Austedo in treating movement disorders. Investors are likely to view this news favorably, as it suggests a promising future for the company and its product lineup.
— Curated by the World Pulse Now AI Editorial System